← Back to Clinical Trials
Recruiting NCT07709858

NCT07709858 CHATEAU Registry: Clinical Outcomes After Transcatheter Aortic Valve Replacement

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07709858
Status Recruiting
Phase
Sponsor Eunpyeong St. Mary's Hospital
Condition Aortic Valve Stenosis
Study Type OBSERVATIONAL
Enrollment 4,000 participants
Start Date 2021-01-01
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Transcatheter Aortic Valve Replacement

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 4,000 participants in total. It began in 2021-01-01 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is a multicenter, retrospective registry study using the CHATEAU Registry. The study will evaluate patients who underwent transcatheter aortic valve replacement between January 2021 and December 2025. The purpose of the study is to assess clinical outcomes and valve performance after TAVR in real-world practice, with a focus on procedural strategies, valve-related factors, and long-term outcomes. Patient clinical information, imaging findings, procedural data, echocardiographic results, and follow-up outcomes will be collected from existing medical records. No additional intervention, treatment, or study-specific visit will be performed.

Eligibility Criteria

Inclusion Criteria: * Adults (≥18 years of age). * Patients who underwent transcatheter aortic valve replacement (TAVR) for severe native aortic valve disease at participating centers. * TAVR performed between January 1, 2021 and December 31, 2025. * Availability of baseline procedural and follow-up clinical data in the institutional registry or medical records. Exclusion Criteria: * Patients with insufficient clinical or procedural data for outcome assessment.

Contact & Investigator

Central Contact

Osung Kwon, MD. PhD

✉ oscaesar@gmail.com

📞 +821037085673

Principal Investigator

Osung Kwon, MD, PhD

PRINCIPAL INVESTIGATOR

The Catholic University of Korea Eunpyeong St. Mary's Hospital

Frequently Asked Questions

Who can join the NCT07709858 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Aortic Valve Stenosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07709858 currently recruiting?

Yes, NCT07709858 is actively recruiting participants. Contact the research team at oscaesar@gmail.com for enrollment information.

Where is the NCT07709858 trial being conducted?

This trial is being conducted at Seoul, South Korea.

Who is sponsoring the NCT07709858 clinical trial?

NCT07709858 is sponsored by Eunpyeong St. Mary's Hospital. The principal investigator is Osung Kwon, MD, PhD at The Catholic University of Korea Eunpyeong St. Mary's Hospital. The trial plans to enroll 4,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology